Editor: Atta-ur-Rahman FRS

Frontiers in Clinical Drug Research-Hematology

Volume 2

eBook: US $89 Special Offer (PDF + Printed Copy): US $163
Printed Copy: US $119
Library License: US $356
ISSN: 2352-3239 (Print)
ISBN: 978-1-68108-182-3 (Print)
ISBN: 978-1-68108-181-6 (Online)
Year of Publication: 2016
DOI: 10.2174/97816810818161160201


Frontiers in Clinical Drug Research – Hematology is an eBook series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of hematological disorders. The scope of the eBook series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs employed in the treatment of anemias, coagulopathies, vascular diseases and hematological malignancies. Reviews in this series also include research on specific antibody targets, therapeutic methods, genetic hemoglobinopathies and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Hematology is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of hematology, oncology and vascular pharmacology.

The second volume of this series features 5 chapters that cover a variety of topics including:

  • - Chronic myeloid leukemia
  • - ispecific and multivalent antibodies
  • - Natural Killer cells therapy for bone marrow transplantation
  • - Nanoparticles in health and disease
  • - Monoclonal antibody therapy for lymphoma


Volume 2 of Frontiers in Clinical Drug Research-Hematology comprises of five comprehensive chapters written by eminent experts covering recent advances in the treatment of lymphoma, bone marrow transplantation, chronic myeloid leukemia and various hematological malignancies.

In the first chapter Marfe and colleagues reviewed the literature related to molecular biology of chronic myeloid leukemia with particular emphasis on agents that target at the molecular level and their resistance mechanisms in order to combat disease.

The treatment of cancer by targeted biologics such as monoclonal antibodies has been shown to be a promising approach. According to recent studies, bi- and multi-specific antibodies have been found to be more effective in fighting against tumor cells. In the second chapter of this eBook, Stanglmaier and Hess present an overview of the current development of bi- and multi-specific antibodies for treatment of B-cell malignancies.

In the third chapter, Martín-Antonio et al., highlight the strengths and weaknesses of Natural Killer cells in fighting Multiple Myeloma and hematological malignancies. They also propose certain guidelines for the development of future trials.

Janousek and colleagues, in chapter 4, shed light on a potentially revolutionary topic i.e., nanoparticles and nanomaterials. They review the role of nanoparticles in the management of hematological and malignant disorders. Phipps and Teo in the last chapter have drawn attention to the importance of new advancements in delivery methods of Monoclonal Antibodies to target the antigens that are present on lymphoma cells.

I would like to acknowledge the efforts of all the contributors for their outstanding contributions. I am also thankful to the team of Bentham Science Publishers, especially Dr. Faryal Sami and Mr. Shehzad Naqvi led by Mr. Mahmood Alam, Director Bentham Science Publishers for their efforts.

Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge